SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

12 days ago

Associate Marketing Pipeline Strategy Cardiometabolic Director

Novo Nordisk

New Jersey, USA (On-site)Full time$153K/yr – $267K/yr
12 days ago

Senior Marketing Pipeline Strategy Cardiometabolic Manager

Novo Nordisk

New Jersey, USA (On-site)Full time$120K/yr – $223K/yr
6 weeks ago

Associate Director, Content Management Authoring Lead

Novo Nordisk

New Jersey, USA (On-site)Full time$153K/yr – $267K/yr
7 weeks ago

Senior Consumer Marketing Manager

Novo Nordisk

New Jersey, USA (On-site)Full time$120K/yr – $223K/yr
5 months ago

Senior Manager - Digital Content Strategy & Production

Novo Nordisk

New Jersey, USA (On-site)Full time$121K/yr – $222K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs

Associate Marketing Pipeline Strategy Cardiometabolic Director

Novo Nordisk

New Jersey, USA (On-site)

$153K/yr - $267K/yrIn-houseFull-timeDirector/executive10+ years exp.
12 days ago

Senior Marketing Pipeline Strategy Cardiometabolic Manager

Novo Nordisk

New Jersey, USA (On-site)

$120K/yr - $223K/yrIn-houseFull-timeSenior level7+ years exp.
12 days ago

Associate Director, Content Management Authoring Lead

Novo Nordisk

New Jersey, USA (On-site)

$153K/yr - $267K/yrIn-houseFull-timeSenior level10+ years exp.
6 weeks ago

Senior Consumer Marketing Manager

Novo Nordisk

New Jersey, USA (On-site)

$120K/yr - $223K/yrIn-houseFull-timeSenior level8+ years exp.
7 weeks ago

Senior Manager - Digital Content Strategy & Production

Novo Nordisk

New Jersey, USA (On-site)

$121K/yr - $222K/yrIn-houseFull-timeSenior level10+ years exp.
5 months ago
Novo Nordisk

Associate Marketing Pipeline Strategy Cardiometabolic Director

New Jersey, USA (On-site)

$153K/yr – $267K/yrDirector/Executive10+ years expFull time

Posted 12 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own shaping early commercialization by driving market assessments, TPP input, regulatory alignment, and cross-functional planning, while smoothing the transition from development to brand teams and continuously optimizing the product launch process.

  • Lead early commercial strategy for pipeline products in the US context
  • Align cross-functional teams across marketing, market access, and medical with global objectives
  • Coordinate knowledge transfer between clinical development and marketing to maximize product potential

Job Description

Responsibilities

  • Cross-Functional Collaboration & Planning: Help the Sr Dir foster early strategic alignment across cross-functional teams including marketing, market access, and medical to ensure a cohesive approach to early product commercialization. Collaborate with global commercial teams as the point of contact
  • Market Assessment and Opportunity Analysis: Oversee completion of thorough market assessments and opportunity analyses to identify target patient populations, unmet needs, and competitive positioning strategies
  • Target Product Profile (TPP) Development Support: Provide strategic input for TPPs, which then inform strategic input for clinical trial and regulatory strategy, to ensure alignment with commercialization goals. Collaborate with clinical and regulatory teams to understand clinical data / patient outcomes, identify market opportunities, address regulatory requirements, and shape product development strategies
  • Regulatory Compliance: Work closely with regulatory affairs to ensure early commercialization strategies comply with regulatory guidelines and industry standards
  • Deliver Early Commercial Strategy: Create early commercialization strategy per pipeline product, describing Where to Play, How to Win, and What to Do, that will maximize the value of the product and serve appropriate patients in the US. This includes: early brand vision, brand positioning, priority customer segments, messaging, value prop, and life cycle plan
  • Commercialization Transition: Facilitate the smooth transition of product strategy (from pipeline development) into TA Brand teams at the appropriate time. Ensure continuity of market research, therapy area knowledge, decision processes, and ongoing TA development activities during pre-launch years. Also, transfer knowledge between clinical development teams and marketing brand/therapy area teams, ensuring clinical insights, patient profiles, and early competitive positioning strategies are transferred to appropriate teams, to maximize product potential
  • Project Management and Coordination: coordinate transition between clinical development and commercialization teams, ensuring milestones are met. Identify and mitigate potential risks or challenges during the transition process, proactively addressing issues to minimize disruptions and ensure continuity of product development efforts
  • Continuous Improvement and Optimization: Develop continuous improvement initiatives to optimize the product transition process, implementing best practices, tools, and methodologies to streamline workflows and enhance efficiency

Requirements

  • Requires a Bachelor’s degree; Master’s degree preferred
  • Requires 10+ years of experience, including product marketing, product launch, product management, pipeline strategy development, new product planning, or related roles within the pharmaceutical industry
  • Requires knowledge of pharmaceutical regulatory requirements
  • Requires knowledge of drug development processes and requirements
  • Requires expert knowledge of the pharmaceutical industry, including competitive market dynamics, and trends, especially within preferred
  • Strategic mindset with ability to develop and execute innovative commercial strategies aligned with NNI objectives and market opportunities
  • Strong planning and organizational skills with high attention to detail and proven track record of results and follow up
  • Ability to manage complexity, including the management of work across competing priorities, functions, and time zones
  • Excellent written and verbal communication and stakeholder management skills, with ability to communicate to/with and influence senior leaders and collaborate with cross-functional teams across the organization
  • Project management skills, with the ability to lead and coordinate complex initiatives involving multiple stakeholders

Benefits

  • Employees are also eligible to participate in Company employee benefit programs including medical, dental and vision coverage; life insurance; disability insurance; 401(k) savings plan; flexible spending accounts; employee assistance program; tuition reimbursement program; and voluntary benefits such as group legal, critical illness, identity theft protection, pet insurance and auto/home insurance.
  • The Company also offers time off pursuant to its sick time policy, flex-able vacation policy, and parental leave policy.

Novo Nordisk

4.3 Glassdoor

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.htmlFor other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.htmlPlease keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Founded in 1923
Copenhagen, Capital Region of Denmark, DNK
66K employees (3,095 in marketing)
www.novonordisk.com
87% recommend to a friend
95% CEO approval

Traffic Signals

Monthly Visitors
503.1K
Monthly Google Ads Budget
$119
Traffic Source Mix
Search
49.5%
Direct
35.6%
Referral
9.2%
Social
4.9%
Paid
0.7%

Headcount Trend

Current headcount: ~66.4K

Marketing Team

Marketing Team Size
2,554 (4% of company)
Median Career Experience
20.5 years
Median Tenure
8.1 years
Marketing Roles Posted (Last 30 Days)
2

People

Marketing Leadership

Ericka Higgins
Ericka Higgins
Vice President, Omnichannel Marketing and Commercial Operations
At the company for 14 years 2 months
Kevin Donahoe
Kevin Donahoe
Vice President, Diabetes Therapy Area Marketing
At the company for 8 years 2 months
Cathy Bonetti
Executive Assistant to VP Marketing
At the company for 6 years 8 months
Monica Singhee
Monica Singhee
Head, Commercial Strategy and Marketing Rare Disease
At the company for 22 years 10 months

Funding

Total Funding
$22M
Last Raise
$22M
Post IPO Equity, 7 years ago

Funding History

  • Dec 2018
    Post IPO Equity • $22M

Recent News

Growing Healthy Places: Mississauga to support children's health and well-being across the city Français
Mar 20, 2025 • Canada NewsWire
2025 North American Inspiring Workplaces Awards Finalists in Association with Employera Announced
Mar 20, 2025 • EIN Presswire
Lifecare scientific updates: CGM symposium in Bergen, consensus recommendations from the Diabetes Technology Society and presentation of data at ATTD 2025
Mar 20, 2025 • TradingView
Oligonucleotides cleavage breakthrough with Vapourtec system
Mar 20, 2025 • PharmiWeb.com
Global Trulicity Market Insights 2025: Key Trends, Market Size, And Growth Forecast
Mar 19, 2025 • EIN Presswire
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
Mar 19, 2025 • BioSpace
Is This Simple Index Fund a Millionaire Maker?
Mar 19, 2025 • The Motley Fool
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas
Mar 19, 2025 • BioSpace
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Mar 18, 2025 • Fierce Pharma
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Mar 18, 2025 • GlobeNewswire News Room
As young Indians take weight loss shots unsupervised, they are landing up in hospitals with this side effect
Feb 11, 2025 • The Indian Express
Ozempic competitors show there’s much to gain in weight loss drugs
Feb 10, 2025 • SmartCompany
Increasing Prevalence Of Diabetes Is Expected To Propel The Growth: Key Driver Transforming the Novolin N Market in 2025
Feb 10, 2025 • EIN Presswire
Leading Driver in the Xultophy 100/3.6 Market 2025: Rising Type 2 Diabetes Prevalence Driving Growth In The Market
Feb 10, 2025 • EIN Presswire
General Catalyst launches EU AI Champions Initiative
Feb 10, 2025 • MobiHealthNews
In the clinic for Feb. 10, 2025
Feb 10, 2025 • BioWorld Financial Watch
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Feb 10, 2025 • The Motley Fool
Leading Driver in the Novolin R Market 2025: Rising Prevalence Of Diabetes Is Expected To Rise The Growth Of Market
Feb 10, 2025 • EIN Presswire
Novo Nordisk (NVO) Investors are Alerted of the Pending Class Action and are Urged to Contact BFA Law by March 25 Deadline
Feb 9, 2025 • Newsfile
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Feb 6, 2025 • GlobeNewswire News Room
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds - and she's not alone
Jan 26, 2025 • Morningstar, Inc.
Tensions rise as Trump presses Denmark PM over Greenland in fiery call
Jan 26, 2025 • The Indian Express
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Jan 26, 2025 • TradingView
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Jan 24, 2025 • GlobeNewswire News Room
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Jan 24, 2025 • BioSpace
Stock market today: Wall Street edges back from its record
Jan 24, 2025 • Connecticut Post
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Jan 24, 2025 • The Motley Fool
Leading Driver in the Esperoct Market 2025: Rising Incidence Of Bleeding Disorders Driving Market Growth
Jan 24, 2025 • EIN Presswire
IMMvention Therapeutix enters collaboration with Novo Nordisk for sickle cell disease therapies
Jan 22, 2025 • Seeking Alpha
Do We Need Humans in the Loop? A Novo Nordisk Exec Weighs In (Video)
Jan 21, 2025 • MedCity News
Peptide Synthesis Industry Set to Double, Reaching USD 1....
Jan 1, 2025 • PharmiWeb.com
A massive diabetes challenge and pharma-tech moonshots, Europe starts 2025 in launch mode
Dec 31, 2024 • Euractiv
Nordnet savers bottom-fished in December, sold off Tesla
Dec 30, 2024 • MarketScreener
What will supercharge European biotech startups?
Dec 30, 2024 • Labs of Latvia
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Dec 29, 2024 • The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Dec 29, 2024 • The Motley Fool
Ozempic: What Rwandan officials say about diabetes, obesity drug?
Dec 28, 2024 • The New Times
David Driscoll’s Top Picks for December 27, 2024
Dec 27, 2024 • BNN Bloomberg
Handelsbanken gets more bullish on Novo Nordisk, upgrades shares
Dec 23, 2024 • thefly.com
NOVO NORDISK : DZ Bank is Neutral
Dec 23, 2024 • MarketScreener
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
Jul 9, 2024 • MarketScreener
Intel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fall
Jul 9, 2024 • Investing.com
Novo Nordisk shares take a hit after a report revealed Eli Lilly’s better weight loss drug
Jul 9, 2024 • Fast Company
Novo Nordisk publicly reprimanded over undisclosed payments, adding to marketing woes in UK
Jul 8, 2024 • FiercePharma
Novo Nordisk A/S - share repurchase programme
Jul 8, 2024 • Globe Newswire
Lilly bests Novo Nordisk in observational study of GLP-1 drugs
Jul 8, 2024 • Endpoints News
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Jul 5, 2024 • Benzinga
Is It Too Late to Buy Novo Nordisk Stock?
Jul 5, 2024 • The Motley Fool
Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
Jul 3, 2024 • SeekingAlpha
Why Novo Nordisk Stock Is Slipping Today
Jul 2, 2024 • The Motley Fool